Dr. Reddy's Laboratories reports Q1 results on July 22 against a backdrop of easing short pressure and cautious options activity — a setup where the positioning story and the fundamental debate are pulling in opposite directions.
The clearest shift heading into the print is the sharp retreat in short sellers. Short interest has fallen roughly 11% over the past week to around 21.5 million shares, reversing a build that peaked in late June. That peak, around June 29, coincided with the tightest borrow conditions of the past year — availability had dropped to just 5.3%, meaning nearly every share in the lending pool was already lent out. Since then, the borrow market has loosened substantially. Availability has recovered to 67%, cost to borrow has retreated to 1.6% from a spike above 8.6% at end-June, and the ORTEX short score has drifted down from above 60 to 57.6 — still moderately elevated but trending lower. The unwinding looks deliberate rather than forced.
Options traders are less relaxed. The put/call ratio at 0.48 runs above its 20-day average of 0.38, with a z-score near 1.2 — not extreme, but pointing to above-average demand for downside protection heading into the earnings date. The stock has also lost ground at precisely the wrong moment: down around 5% for the month and 4.5% for the week to close at $12.60, so the bulls are defending a weaker technical starting point than they'd prefer.
The fundamental debate centres on margin pressure. A recent ORTEX note flags intensifying generic competition in key markets as the primary headwind, with near-term earnings visibility weakening even as the company pursues API and emerging-market expansion. Valuation has compressed accordingly — the trailing PE has declined by more than a point over the past month to around 21x, and the price-to-book has slipped below 2.3x. Analyst coverage for the NYSE-listed ADR is thin and the most recent meaningful action was HSBC's upgrade to Buy in June 2025 at a target of $16.90, implying meaningful upside from current levels; Barclays has maintained Overweight through successive adjustments, though its most recent target figures reflect earlier reporting periods and the wide gap between those levels and the current $12.60 ADR price warrants caution in direct comparison. On the positive side, the 12-month forward earnings growth score ranks in the 62nd percentile, and the dividend score ranks near the top of the universe at the 95th percentile, giving longer-duration holders a degree of income cushion.
The July 22 print is ultimately a test of whether Dr. Reddy's can demonstrate that margin deterioration from generic competition is bottoming — and whether that is enough to close the gap between where the stock trades and where more constructive analysts believe it belongs.
See the live data behind this article on ORTEX.
Open RDY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
